Heron Therapeutics (NASDAQ:HRTX) has been assigned a $40.00 target price by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 49.53% from the company’s current price.
Several other research firms have also weighed in on HRTX. Lake Street Capital set a $42.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Thursday. Evercore ISI began coverage on shares of Heron Therapeutics in a report on Thursday. They set an “outperform” rating and a $56.00 target price on the stock. Northland Securities restated a “buy” rating and set a $55.00 target price on shares of Heron Therapeutics in a report on Monday, March 26th. BidaskClub upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 24th. Finally, Oppenheimer set a $34.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 27th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $35.92.
Shares of NASDAQ:HRTX traded down $1.15 during midday trading on Friday, hitting $26.75. 1,547,176 shares of the company’s stock traded hands, compared to its average volume of 1,972,856. The firm has a market capitalization of $1,970.00, a price-to-earnings ratio of 7.33 and a beta of 1.88. Heron Therapeutics has a twelve month low of $12.70 and a twelve month high of $32.70.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.29). The business had revenue of $10.05 million for the quarter, compared to analyst estimates of $9.00 million. Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. equities research analysts forecast that Heron Therapeutics will post -2.5 EPS for the current year.
In related news, VP Kimberly Manhard sold 7,584 shares of Heron Therapeutics stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total transaction of $151,680.00. Following the sale, the vice president now owns 7,584 shares of the company’s stock, valued at approximately $151,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Barry D. Quart sold 100,000 shares of Heron Therapeutics stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $24.75, for a total transaction of $2,475,000.00. Following the sale, the chief executive officer now directly owns 167,993 shares in the company, valued at approximately $4,157,826.75. The disclosure for this sale can be found here. Insiders have sold a total of 225,584 shares of company stock worth $6,141,680 in the last ninety days. 19.93% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in HRTX. Perceptive Advisors LLC bought a new stake in shares of Heron Therapeutics in the 3rd quarter worth about $5,329,000. Rock Springs Capital Management LP bought a new stake in shares of Heron Therapeutics in the 4th quarter worth about $4,525,000. ArrowMark Colorado Holdings LLC increased its position in shares of Heron Therapeutics by 33.1% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 838,117 shares of the biotechnology company’s stock worth $15,170,000 after purchasing an additional 208,548 shares during the last quarter. Rubric Capital Management LP increased its position in shares of Heron Therapeutics by 11.8% in the 3rd quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock worth $30,685,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Monashee Investment Management LLC bought a new stake in shares of Heron Therapeutics in the 4th quarter worth about $3,620,000.
TRADEMARK VIOLATION WARNING: “Heron Therapeutics (HRTX) Given a $40.00 Price Target by Cantor Fitzgerald Analysts” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/heron-therapeutics-hrtx-given-a-40-00-price-target-by-cantor-fitzgerald-analysts.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.